Core Insights - Altimmune, Inc. has appointed Dr. Christophe Arbet-Engels as Chief Medical Officer to lead the Phase 3 development of pemvidutide for metabolic dysfunction-associated steatohepatitis (MASH) [1][2] - Dr. Arbet-Engels brings over 30 years of experience in clinical development, regulatory approvals, and commercial launches, which will be crucial for advancing pemvidutide [2] - The company aims to establish a new standard of care in treating hepato-metabolic disorders, with upcoming data from the IMPACT trial and ongoing Phase 2 trials in Alcohol Use Disorder and Alcohol-associated Liver Disease [2] Company Overview - Altimmune is a late clinical-stage biopharmaceutical company focused on developing peptide-based therapeutics for liver and cardiometabolic diseases [6] - The lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist targeting MASH, Alcohol Use Disorder, Alcohol-associated Liver Disease, and obesity [6] Leadership Transition - Dr. Scott Harris, the previous Chief Medical Officer, will retire but remain as a Senior Strategic Advisor until February 2026 [1][2] - Dr. Arbet-Engels has previously held senior roles at X4 Pharmaceuticals, Neurogastrx, Millendo Therapeutics, and Poxel Pharmaceuticals, contributing to successful regulatory processes and clinical programs [2] Inducement Grant Details - Dr. Arbet-Engels will receive options to purchase 450,000 shares and 150,000 restricted stock units (RSUs) as part of his compensation package [3][4] - The options will vest over four years, with one-fourth vesting on the one-year anniversary of the grant date [4][5] - The RSUs will also vest over four years, with one-fourth vesting on the one-year anniversary and the remainder in three equal installments [5]